

# Patient-Reported Outcomes in ZUMA-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Mahmoud Elsayy, MD, MSc<sup>1</sup>; Julio C. Chavez, MD<sup>2</sup>; Irit Avivi, MD<sup>3</sup>; Jean-François Larouche, MD<sup>4</sup>; Luciano Wannesson, MD<sup>5</sup>; Kate Cwynarski, FCRPATH, PhD<sup>6</sup>; Keren Osman, MD<sup>7</sup>; Kelly Davison, MD, PhD<sup>8</sup>; Jakob D. Rudzki, MD<sup>9</sup>; Saurabh Dahiya, MD, FACP<sup>10</sup>; Kathleen Dorritie, MD<sup>11</sup>; Samantha Jaglowski, MD<sup>12</sup>; John Radford, MD, FRCP, FMedSci<sup>13</sup>; Franck Morschhauser, MD, PhD<sup>14</sup>; David Cunningham, MD, FRCP, FMedSci<sup>15</sup>; Alejandro Martin Garcia-Sancho, MD<sup>16</sup>; Dimitrios Tzachanis, MD, PhD<sup>17</sup>; Matthew L. Ulrickson, MD<sup>18</sup>; Reem Karmali, MD<sup>19</sup>; Natasha Kekre BSc, MD, MPH, FRCPC<sup>20</sup>; Catherine Thieblemont, MD, PhD<sup>21</sup>; Gunilla Enblad, MD, PhD<sup>22</sup>; Peter Dreger, MD, PhD<sup>23</sup>; Ram Malladi, MD<sup>24,25</sup>; Namita Joshi, PhD<sup>26</sup>; Wei-Jih Wang, PhD<sup>26</sup>; Caitlyn T. Solem, PhD<sup>26</sup>; Julia Thornton Snider, PhD<sup>27</sup>; Christina To, MD<sup>27</sup>; and Marie José Kersten, MD, PhD<sup>28</sup>

<sup>1</sup>Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada; <sup>2</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>3</sup>Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; <sup>4</sup>CHU de Québec, Hôpital de l'Enfant-Jésus, Québec, QC, Canada; <sup>5</sup>Istituto Oncologico della Svizzera Italiana, Switzerland; <sup>6</sup>University College London Hospitals NHS Foundation Trust, London, United Kingdom; <sup>7</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA; <sup>8</sup>McGill University Health Centre, Montreal, QC, Canada; <sup>9</sup>The Medical University of Innsbruck, University Clinic for Internal Medicine, Innsbruck, Austria; <sup>10</sup>University of Maryland Medical Center, Baltimore, MD, USA; <sup>11</sup>UPMC Hillman Cancer Center, Pittsburgh, PA, USA; <sup>12</sup>The Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA; <sup>13</sup>The Christie NHS Foundation Trust and the University of Manchester, Manchester, United Kingdom; <sup>14</sup>University of Lille, CHU Lille, France; <sup>15</sup>The Royal Marsden NHS Foundation Trust, London, United Kingdom; <sup>16</sup>Salamanca University Hospital, IBSAL, CIBERONC, Salamanca, Spain; <sup>17</sup>University of California, San Diego, La Jolla, CA, USA; <sup>18</sup>Banner MD Anderson Cancer Center, Gilbert, AZ, USA; <sup>19</sup>Northwestern University, Chicago, IL, USA; <sup>20</sup>The Ottawa Hospital, Ottawa, ON, Canada; <sup>21</sup>University of Paris, Hôpital Saint-Louis, Hemato-oncology, DMU DHI, Paris, France; <sup>22</sup>Uppsala University Hospital, Uppsala, Sweden; <sup>23</sup>University of Heidelberg, Heidelberg, Germany; <sup>24</sup>Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; <sup>25</sup>University Hospitals Birmingham NHS Foundation Trust; <sup>26</sup>OPEN Health, Bethesda, MD, USA; <sup>27</sup>Kite, a Gilead Company, Santa Monica, CA, USA; and <sup>28</sup>Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands, on behalf of HOVON/LLPC

## BACKGROUND


- Outcomes are poor for patients with large B-cell lymphoma (LBCL) who relapse early or are refractory to first-line therapy. Furthermore, patients receiving second-line standard-of-care (SOC) therapy often report poor health-related quality of life (QoL)<sup>1</sup>
- ZUMA-7 (NCT03391466) is a pivotal Phase 3, randomized, open-label, multicenter study of axi-cel (an autologous anti-CD19 chimeric antigen receptor [CAR] T-cell therapy) versus SOC in second-line relapsed/refractory (R/R) LBCL
  - Primary analysis results were presented at ASH 2021 (plenary, December 12)
- Axi-cel is an approved therapy for patients with R/R LBCL after 2 or more lines of therapy
  - ZUMA-1 (NCT02348216) investigated the safety and efficacy of axi-cel in patients with refractory LBCL
    - A long-term follow-up analysis recently presented at ASH 2021 demonstrated a 5-year overall survival (OS) rate of 43% after a median follow-up of 63 months<sup>2</sup>

## OBJECTIVE

- Here, we report the first comparative analysis of patient-reported outcomes (PROs) with CAR T-cell therapy versus SOC as second-line treatment in R/R LBCL in ZUMA-7

## METHODS

Figure 1. ZUMA-7 Study Schema and Endpoints



<sup>1</sup>Refractory disease was defined as no CR to 1L therapy; relapsed disease was defined as CR followed by biopsy-proven disease relapse ≤12 months from completion of 1L therapy. <sup>2</sup>Axi-cel patients underwent leukapheresis followed by conditioning chemotherapy with cyclophosphamide (500 mg/m<sup>2</sup>/day) and fludarabine (30 mg/m<sup>2</sup>/day) 5, 4, and 3 days before receiving a single axi-cel infusion (target intravenous dose, 2 × 10<sup>6</sup> CAR T cells/kg). <sup>3</sup>Protocol-defined SOC regimens included R-GDP, R-DHAP, R-ICE, or R-ESHAP. <sup>4</sup>EFS was defined as time from randomization to the earliest date of disease progression per Lugano Classification, commencement of new lymphoma therapy, or death from any cause. <sup>5</sup>CR, complete response; EFS, event-free survival; HDT-ASCT, high-dose therapy with autologous stem cell rescue; LBCL, large B-cell lymphoma; LTFU, long-term follow-up; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; PRO, patient-reported outcome; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-ESHAP, rituximab, etoposide, methylprednisolone, cytarabine, and cisplatin; R-GDP, rituximab, gemcitabine, cisplatin, and dexamethasone; R-ICE, rituximab, ifosfamide, carboplatin, and etoposide; R/R, relapsed/refractory; sAAIPI, second-line age-adjusted International Prognostic Index; SOC, standard of care.

Table 1. PRO Instruments

Instrument	Description	Scales/Domains
<b>EORTC QLQ-C30</b>	Cancer-specific 30-item questionnaire including global health status, functional, and symptom scales <sup>6,7</sup>	<ul style="list-style-type: none"> <li>Functional scales: physical, role, emotional, cognitive, and social functioning</li> <li>Symptom scales: fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties</li> </ul>
<b>EQ-5D-5L</b>	General questionnaire with 5 QoL domains plus a global assessment <sup>8</sup>	<ul style="list-style-type: none"> <li>Mobility, self-care, usual activities, pain/discomfort, and anxiety/depression</li> <li>VAS (rating of global assessment of their current [day of assessment] state of health)</li> </ul>
<b>WPAI: General Health</b>	Measure of work productivity and activity impairment <sup>9</sup>	<ul style="list-style-type: none"> <li>Absenteeism, presenteeism, overall work impairment, and activity impairment</li> </ul>

EORTC, European Organization for Research and Treatment of Cancer; PRO, patient-reported outcome; QLQ-C30, Quality of Life Questionnaire-Core 30; QoL, quality of life; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.

- Assessments (Figure 1, Table 1) were taken at baseline (prior to treatment), Day 50, Day 100, Day 150, Month 9, and every 3 months thereafter from randomization up to 24 months or time of event-free survival event (disease progression, death from any cause, or new lymphoma therapy), whichever occurred first
- The analysis population (QoL analysis set) included all patients who had a baseline PRO and ≥1 measure completed at Day 50, Day 100, or Day 150
- Prespecified hypotheses for 3 PRO domains (European Organization for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire-Core 30 [QLQ-C30] Physical Functioning, EORTC QLQ-C30 Global Health Status/QoL, and EQ-5D-5L visual analog scale [VAS]) were tested using a mixed-effect model with repeated measures at Day 100 and subsequent time points if previous time points were statistically significant
- A clinically meaningful change was defined as 10 points for each EORTC QLQ-C30 score, 7 points for EQ-5D-5L VAS score, and 0.06 for the EQ-5D-5L index<sup>10,11</sup>
- Exploratory analyses on other domains of EORTC QLQ-C30 and EQ-5D-5L were also performed<sup>10,12</sup>

## RESULTS


Table 2. Baseline Characteristics: QoL Analysis Set

Characteristic, n (%)	Axi-Cel N=165	SOC N=131	Overall N=296
<b>Age ≥65 years</b>	46 (28)	42 (32)	88 (30)
<b>sAAIPI of 2-3</b>	69 (42)	56 (43)	125 (42)
<b>Response to 1L therapy at randomization</b>			
Primary refractory	119 (72)	89 (68)	208 (70)
Relapse ≤12 mo of 1L therapy	46 (28)	42 (32)	88 (30)
<b>Double-/triple-hit status per investigator</b>			
HGBL (double-/triple-hit)	35 (21)	22 (17)	57 (19)
Negative	102 (62)	76 (58)	178 (60)
Not tested	28 (17)	33 (25)	61 (21)

1L, first-line; axi-cel, axicabtagene ciloleucel; HGBL, high-grade B-cell lymphoma; sAAIPI, second-line age-adjusted International Prognostic Index; SOC, standard of care.

- Of 359 patients enrolled in the ZUMA-7 study, 296 patients (82%) had baseline PROs and ≥1 follow-up measure and were included for analysis (QoL analysis set)
- Overall, 70% of patients had primary refractory disease, 42% had high second-line age-adjusted International Prognostic Index (2-3), and 30% were ≥65 years old (Table 2)
- Using Global Health Status/QoL as a representative measure of the EORTC QLQ-C30, 208 patients (70%) completed the Day 100 assessment (88% axi-cel; 47% SOC)


Figure 2. Change From Baseline for Prespecified PRO Endpoints



Axi-cel, axicabtagene ciloleucel; EORTC, European Organization for Research and Treatment of Cancer; PRO, patient-reported outcome; QLQ-C30, Quality of Life Questionnaire-Core 30; QoL, quality of life; SOC, standard of care; VAS, visual analog scale. Evaluated via mixed-effect model with repeated measures. Statistical significance and clinical meaningfulness coincide for all except for EORTC QLQ-C30 Global Health Status/QoL at Day 150, which was less than a 10-point change (9.8).

- For patients in the QoL analysis set treated with axi-cel versus SOC, there was a statistically significant and clinically meaningful difference in mean change of scores from baseline at Day 100 in favor of axi-cel on all prespecified PRO domains (Figure 2)
  - Sensitivity analyses controlling for covariates and patterns of missingness showed similar results with retained significance at Day 100


Figure 3. Return to Baseline for Prespecified PRO Endpoints



Axi-cel, axicabtagene ciloleucel; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire-Core 30; QoL, quality of life; SOC, standard of care; VAS, visual analog scale. Evaluated via mixed-effect model with repeated measures. Statistical significance and clinical meaningfulness coincide for all except for EORTC QLQ-C30 Global Health Status/QoL at Day 150, which was less than a 10-point change (9.8). Shading indicates when the QoL measure is not statistically different from baseline.

- The mean estimated scores for the axi-cel arm returned to or exceeded scores at baseline by Day 100 – Day 150 (Months 3 – 5) versus Month 9 or later for the SOC arm (Figure 3)


Figure 4. Change From Baseline for EORTC QLQ-C30 Functional Scales



\*P<0.05. Axi-cel, axicabtagene ciloleucel; EORTC, European Organization for Research and Treatment of Cancer; QLQ-C30, Quality of Life Questionnaire-Core 30; QoL, quality of life; SOC, standard of care. Evaluated via mixed-effect model with repeated measures. Symptom scales not shown.

- Additional exploratory analyses of PRO endpoints also showed improvements with axi-cel over SOC (Figure 4)
- The differences in change from baseline were statistically significant (P<0.05) in favor of axi-cel for
  - Nausea and vomiting, diarrhea, insomnia, and appetite loss measures at Day 100
  - Role functioning at Day 100 and Day 150
  - Social functioning, fatigue, and dyspnea measures at Day 100, Day 150, and Month 9

Figure 5. Change From Baseline for Work Productivity and Activity Impairment



\*P<0.05. Axi-cel, axicabtagene ciloleucel; GH, general health; SOC, standard of care; WPAI, Work Productivity and Activity Impairment. Evaluated via mixed-effect model with repeated measures. \*P<0.05. WPAI activities impairment included both employed and not employed patients. The other 3 questions were asked of employed patients only.

- Patients treated with axi-cel had statistically significant (P<0.05) lower mean absenteeism and lower mean activities impairment at Day 100 (Figure 5)

## CONCLUSIONS

- ZUMA-7, the first randomized, global, multicenter Phase 3 study of axi-cel versus SOC in second-line R/R LBCL, demonstrates that treatment with axi-cel results in clinically meaningful improvement in QoL over SOC at Day 100 as measured by multiple validated PRO instruments
  - Score comparisons at later time points warrant cautious interpretation because attrition due to disease progression, new lymphoma therapy, or death was disproportionately higher on the SOC arm and may select patients with the best outcomes
- The data also suggest faster recovery to pretreatment QoL with axi-cel compared with SOC
- The superior clinical outcomes and patient experience with axi-cel over SOC should help inform treatment choices in second-line R/R LBCL

## ACKNOWLEDGMENTS

The authors would like to thank and acknowledge all ZUMA-7 investigators and contributing Kite members as well as ZUMA-7 patients, families, friends, and caregivers for their contributions to this research

This study was funded by Kite

Medical writing support was provided by Jennifer Yang, PhD, and Skye Geherin, PhD, of Nexus Global Group Science LLC, funded by Kite

## REFERENCES

- Lin V, et al. *J Clin Oncol*. 2020;38:e20070.
- Jacobson CA, et al. *ASH 2021 Abstract #1764*.
- Swerdlow SH, et al. *Blood*. 2016;127:2375-2390.
- Cheson BD, et al. *J Clin Oncol*. 2014;32:3059-3068.
- Aaronson NK, et al. *J Natl Cancer Inst*. 1993;85:365-376.
- Fayers P, et al. *The EORTC QLQ-C30 Scoring Manual (3rd Edition)*. 2001.
- Herdman M, et al. *Qual Life Res*. 2011;20:1727-1736.
- Pickard AS, et al. *Value Health*. 2019;22:931-941.
- Reilly MC, et al. *Pharmacoeconomics*. 1993;4:353-365.
- Maringwa JT, et al. *Support Care Cancer*. 2011;19:1753-1760.
- Pickard AS, et al. *Health Qual Life Outcomes*. 2007;5:70.
- Thieblemont C, et al. *Br J Haematol*. 2020;189:84-96.

## DISCLOSURES

ME: honoraria from Kite, Celgene/Bristol Myers Squibb, Novartis, Pfizer, and Janssen; and consultancy or advisory role for Kite, Bristol Myers Squibb, Novartis, Pfizer, and Janssen.

Full author disclosures are available at the following Quick Response (QR) code:



Copies of this poster obtained through QR code are for personal use only and may not be reproduced without permission from the author of this poster.



## FULL AUTHOR DISCLOSURES

**JCC:** consultancy fees for Kite, AbbVie, Janssen, ADC Therapeutics, Karyopharm, Kymera, Genmab, Novartis; speakers' bureau participation for MorphoSys, Epizyme, Bristol Myers Squibb, BeiGene, AstraZeneca; research funding from AstraZeneca, Merck, ADC Therapeutics, Adaptive. **IA:** speakers' bureau participation for Kite and Novartis. **JFL:** no financial relationships to disclose. **LW:** consultancy or advisory role for Novartis, MSD, Bristol Myers Squibb, AstraZeneca, and Roche; research funding from Roche; and expert testimony from AstraZeneca and Novartis. **KC:** consultancy or advisory role for Kite, Roche, Takeda, Celgene, Atara, Gilead, Janssen, and Incyte; speakers' bureau for Roche, Takeda, Kite, Gilead, and Incyte; and travel support from Roche, Takeda, Kite, Janssen, and Celgene/Bristol Myers Squibb. **KO:** honoraria from and consultancy or advisory role for Kite. **KD:** consultancy or advisory role for Merck, AstraZeneca, Janssen, Novartis, Gilead, AbbVie, and Celgene. **JDR:** consultancy or advisory role with Kite, Novartis, Amgen, MSD, Roche, and Celgene/Bristol Myers Squibb; speakers' bureau for Kite, Novartis, and Roche; and research funding from Kite and Novartis. **SD:** consultancy or advisory role for Kite, Atara Biotherapeutics, and Bristol Myers Squibb; research funding from Jazz Pharmaceuticals and Miltenyi Biotec. **KD:** researching funding from Kite, Juno/Bristol Myers Squibb, Hoffman-La Roche, and Janssen. **SJ:** consultancy or advisory role for Kite, Juno, Novartis, Takeda, and CRISPR Therapeutics; research funding from Kite and Novartis. **JR:** stock or other ownership in ADC Therapeutics and AstraZeneca; honoraria from Takeda, ADCT, and Bristol Myers Squibb; consultancy or advisory role for Takeda, ADCT, Bristol Myers Squibb, and Novartis; speakers' bureau from Takeda and ADCT; research funding from Takeda; and expert testimony from Takeda and ADCT. **FM:** consultancy or advisory role for Roche, Bristol Myers Squibb, Gilead, Epizyme, Genmab, Novartis, and AbbVie; speakers' bureau participation from Roche; expert testimony from Roche and Genentech. **DC:** research funding from MedImmune, AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene, and Roche. **AMGS:** honoraria from Roche, Celgene, Janssen, Servier, and Gilead; consultancy or advisory role for Roche, Celgene/Bristol Myers Squibb, MorphoSys, Kyowa Kirin, Clinigen, EUSA Pharma, Novartis, Gilead, Servier, and Incyte; research funding from Janssen; expert testimony from Gilead; and travel support from Roche, Celgene, Servier, and Kern Pharma. **DT:** consultancy or advisory role for Partner, Takeda, EUSA, Kite, Kyowa Kirin, and Magenta; speakers' bureau participation for Takeda and Kite; and research funding from Bristol Myers Squibb, Kite, Genentech, Incyte, and Fate Therapeutics. **MLU:** no relevant financial relationships to disclose. **RK:** consultancy or advisory role for BeiGene, Kite, MorphoSys, Karyopharm, Celgene/Bristol Myers Squibb, Genentech, Roche, Janssen, and Pharmacyclics; speakers' bureau from AstraZeneca, BeiGene, Kite, and MorphoSys; research funding from Kite, Bristol Myers Squibb/Celgene, and Takeda. **NK:** honoraria from Gilead, Novartis, and Celgene; and consultancy or advisory role for Gilead, Novartis, and Celgene. **CTh:** honoraria from Bristol Myers Squibb/Celgene, AbbVie, Takeda, Novartis, Roche, Kite, and Incyte; consultancy or advisory role for Bristol Myers Squibb/Celgene, AbbVie, Takeda, Roche, Novartis, Kite, and Incyte; and travel support from Bristol Myers Squibb/Celgene, Takeda, Roche, Novartis, and Kite. **GE:** consultancy or advisory role with Kite, and Gilead Sciences. **PD:** consultancy or advisory role for AbbVie, AstraZeneca, bluebird bio, Bristol Myers Squibb, Gilead Sciences, Janssen, and Novartis; and research funding from Riemser. **RM:** honoraria from Gilead; consultancy or advisory role Gilead Science; and travel support from Gilead. **NJ:** employment with OPEN Health; consultancy or advisory role and research funding from Kite and various clients via employment. **WJW:** consultancy or advisory role for Kite and additional companies through employment with OPEN Health; research funding from Kite and additional companies through employment with OPEN Health. **CTS:** employment with OPEN Health; consultancy or advisory role for Kite through employment at OPEN Health; research funding from multiple clients through employment at OPEN Health. **JTS:** employment with Kite; stock or other ownership in Gilead Sciences. **CTo:** employment with Kite; stock or other ownership in Gilead Sciences. **MJK:** honoraria from Kite, Novartis, Miltenyi Biotec, Roche, and Celgene/Bristol Myers Squibb; consultancy or advisory role for Kite, Roche, Celgene/Bristol Myers Squibb, Novartis, and Miltenyi Biotec; research funding from Kite, Roche, Takeda, and Celgene; and travel support from Kite, Roche, Novartis, and Miltenyi Biotec.